Publications

2018

Tabbo F, Nottegar A, Guerrera F, Migliore E, Luchini C, Maletta F, et al. Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. Hum Pathol. 2018;75:167-178.
Zhang Y, Mun SR, Linares JF, Ahn JW, Towers CG, Ji CH, et al. ZZ-dependent regulation of p62/SQSTM1 in autophagy. Nat Commun. 2018;9(1):4373.
D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JM, Croyle J, Liu Y-, et al. Characterization of CD34-deficient myofibroblastomas of the breast. Breast J. 2018;24(1):55-61.
Wang Z, Cao S, Morris JS, Ahn J, Liu R, Tyekucheva S, et al. Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. iScience. 2018;9:451-460.
Hissong E, Jessurun J, Yantiss RK. Findings in exudates can help distinguish benign gastric ulcers from ulcerated adenocarcinomas. Histopathology. 2018;73(2):215-219.
Cai L, Tsai Y-, Wang P, Wang J, Li D, Fan H, et al. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell. 2018;72(2):341-354.e6.
Patel SS, Dorfman DM. Leukemic-phase progression of aleukemic mast cell leukemia. Blood. 2018;131(21):2406.
van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-2124.
Nowinski S, Santaolalla A, O'Leary B, Loda M, Mirchandani A, Emberton M, et al. Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. Oncotarget. 2018;9(16):12812-12824.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700